1. In this randomized controlled trial, cabozantinib significantly improved progression-free survival in patients with progressive pancreatic and extra-pancreatic neuroendocrine tumors. ...
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
1. Progression-free and overall survival was comparable in both the intervention and control groups. 2. Serious adverse events were more ...
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
1. The probability of progression-free survival at 12 months was 0.57 in the experimental group (cabozantinib plus nivolumab and ipilimumab) ...
1. Telaglenastat addition to cabozantinib did not show improvements in clinical benefit. 2. Adverse events of grades 3 or 4 ...
1. Objective response rate was 35%, with 1 patient showing a complete response and 7 showing a partial response. 2. ...
1. Intracranial response rate of 55% was reported in patients receiving cabozantinib with progressing brain metastases with no concomitant brain-directed ...
1. Progression-free survival was longer in patients in the cabozantinib group (9.0 months) than in the sunitinib group (5.6 months). ...
